DGAP-News: Cytos Biotechnology Presents Latest Data on the Mechanism of Action of QbG10 for the Treatment of Allergic Asthma at the 3rd International Conference on Drug Discovery and Therapy
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Research
Update
Cytos Biotechnology Presents Latest Data on the Mechanism of Action of
QbG10 for the Treatment of Allergic Asthma at the 3rd International
Conference on Drug Discovery and Therapy
10.02.2011 / 07:00
---------------------------------------------------------------------
Schlieren (Zurich), Switzerland, February 10, 2011 - Cytos Biotechnology
Ltd (SIX:CYTN) today announced that PD Dr. Martin Bachmann, CSO of Cytos,
will present latest data on the mechanism of action of CYT003-QbG10
(QbG10), a safe and efficacious drug candidate for the treatment of
allergic asthma and rhinitis, at the 3rd International Conference on Drug
Discovery and Therapy in Dubai.
QbG10 is a Toll-like receptor 9 agonist with clinical proof-of-concept in
allergic asthma and rhinitis. Allergic Asthma is a disease primarily
mediated by type 2 T helper cells (Th2). Th2 cells influence the asthmatic
response by secreting substances which recruit inflammatory cells into the
lungs, increase mucus production in the airways and cause airway
hyper-reactivity. The resultant obstruction of the airways is the most
critical aspect of asthma. Therefore, blocking Th2 cells is an important
goal for the treatment of asthma. Researchers from Cytos Biotechnology have
now identified two ways by which the Toll-like receptor 9 agonist QbG10
blocks Th2 responses. Firstly, QbG10 induces interferon alpha, a factor
that directly inhibits Th2 cells. Secondly they showed QbG10 induces ICOS
ligand, a protein which causes generation of a special subset of
anti-inflammatory T cells called regulatory T cells. Such regulatory T
cells are known to be capable of blocking Th2 cell activity. Hence, QbG10
controls asthma by directly inhibiting Th2 responses and by fostering the
generation of regulatory T cells.
Dr Martin Bachmann, CSO of Cytos Biotechnology commented: 'These new data
provide an explanation of the mechanism of action of QbG10. This finding is
not only important for the further development and registration of this new
therapeutic modality but it will possibly also shed light on the etiology
of this widespread disease.'
For further information please contact:
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner(at)cytos.com
Website: www.cytos.com
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which five are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 77 full-time equivalents.
Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss
Exchange (SIX:CYTN).
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'will', 'designed', 'intended' or other
similar expressions. These forward-looking statements are subject to a
variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments. This document does not constitute an offer
or invitation to subscribe or purchase any securities of Cytos
Biotechnology Ltd.
End of Corporate News
---------------------------------------------------------------------
10.02.2011 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Regulierter Markt in SIX; Freiverkehr in
Berlin, München, Stuttgart; Open Market in
Frankfurt
End of News EquityStory AG News-Service
---------------------------------------------------------------------
111632 10.02.2011
Datum: 10.02.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 33180
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology Presents Latest Data on the Mechanism of Action of QbG10 for the Treatment of Allergic Asthma at the 3rd International Conference on Drug Discovery and Therapy"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
